Literature DB >> 11533747

Primary hyperparathyroidism and pregnancy.

M A Fouda1.   

Abstract

OBJECTIVE: The coexistence of primary hyper-parathyroidism and pregnancy is very rare worldwide. It carries serious complications to the mother and fetus, therefore, early diagnosis and management is of paramount importance.
METHODS: Over a period of 16 years from 1982-1997, 24 patients with primary hyperparathyroidism were identified from the central diagnostic index data base of King Khalid University Hospital. Out of these, only 3 women with primary hyperparathyroidism complicating pregnancy were identified.
RESULTS: All 3 women were in the fourth decade. Two of them had coexisting vitamin D deficiency with initially normal serum calcium and were misdiagnosed as cases of osteomalacia while the third had very high serum calcium on first presentation. A single parathyroid adenoma was identified in all 3 patients with 2 undergoing surgical removal of the adenoma. The third patient unfortunately had an abortion. The babies of the first 2 patients were born healthy with no complications.
CONCLUSION: Primary hyperparathyridism, even though rare in pregnancy, carries risks to the mother and fetus and therefore early screening for asymptomatic hyper-parathyroidism in all women of childbearing age and in the early antenatal period of pregnant women is recommended.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11533747

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  2 in total

1.  Seventeen Cases of Primary Hyperparathyroidism in Pregnancy: A Call for Management Guidelines.

Authors:  Aimee Natasha DiMarco; Karim Meeran; Ioannis Christakis; Vinpreet Sodhi; Catherine Nelson-Piercy; Neil Samuel Tolley; Francesco Fausto Palazzo
Journal:  J Endocr Soc       Date:  2019-02-20

2.  Undiagnosed Primary Hyperparathyroidism and Recurrent Miscarriage: The First Prospective Pilot Study.

Authors:  Aimee DiMarco; Ioannis Christakis; Vasilis Constantinides; Lesley Regan; F Fausto Palazzo
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.